title: Inhibition of Donor-Reactive CD8+ T Cell Responses by Selective CD28 Blockade Is Independent of Reduced ICOS Expression.
abstract: Programmed T cell differentiation is critically influenced by the complement of costimulatory and coinhibitory signals transmitted during initial antigen encounter. We previously showed that selective CD28 blockade with novel domain antibodies that leave CTLA-4-mediated coinhibitory signaling intact resulted in more profound attenuation of donor-reactive T cell responses and improved graft survival in a murine transplant model. Selective CD28 blockade was also associated with decreased ICOS expression on donor-reactive CD8+ T cell responses as compared to CTLA-4 Ig, but the functional importance of this reduced ICOS expression was not known. In this study, we created retrogenic donor-reactive CD8+ T cells that overexpress ICOS in order to determine whether reduced ICOS expression mechanistically underlies the increased efficacy of selective CD28 blockade in controlling graft-specific T cell responses as compared to conventional costimulation blockade with CTLA-4 Ig. Results indicated that the ability of selective CD28 blockade to blunt donor-reactive CD8+ T cell expansion following transplantation was independent of its ability to inhibit ICOS expression. Furthermore, we have previously published that 2B4 coinhibitory signals are functionally important for controlling graft-specific CD8+ T cell responses in mice treated with CD28 blockade. Here we used a co-adoptive transfer approach to determine that 2B4 coinhibitory signals on antigen-specific CD8+ T cells function in a cell-intrinsic manner to limit ICOS expression in the setting of selective CD28 blockade.
authors.affiliation: Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322, United States of America.
authors.forename: Danya
authors.initials: D
authors.lastname: Liu
authors.affiliation: Bristol-Myers Squibb Company, Princeton, NJ, United States of America.
authors.forename: Suzanne J
authors.initials: SJ
authors.lastname: Suchard
authors.affiliation: Bristol-Myers Squibb Company, Princeton, NJ, United States of America.
authors.forename: Steve G
authors.initials: SG
authors.lastname: Nadler
authors.affiliation: Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322, United States of America.
authors.forename: Mandy L
authors.initials: ML
authors.lastname: Ford
mesh_terms: D000818:Animals; D018106:CD28 Antigens / Q000037:antagonists & inhibitors / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D006789:Host vs Graft Reaction; D060889:Inducible T-Cell Co-Stimulator Protein / Q000235:genetics / Q000378:metabolism*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
chemical_list: D018106:CD28 Antigens; C556694:Icos protein, mouse; D060889:Inducible T-Cell Co-Stimulator Protein